Zusammenfassung
Fokale Veränderungen in der Leber werden seit Einführung der Abdomen-Sonographie mit einer zunehmenden Häufigkeit nachgewiesen. Diese in der Regel zufälligen Entdeckungen bedeuten für Patienten und Patientinnen einen akuten Leidensdruck, weil ganz vordergründig die potentiell bösartige Genese des Befundes in Betracht gezogen werden muss. Mit der kontroversiellen Beobachtung in den Achtzigerjahren des letzten Jahrhunderts, dass mit Einführung von Ovulationshemmern mit hohem Östrogengehalt die Inzidenz von Adenomen, deren natürlicher Verlauf sich von denen aus chirurgischen bzw. autoptischen Studien bekannten deutlich unterschied, zugenommen hatte, war die Weichenstellung zur modernen pathophysiologischen und prognostischen Differenzierung gelegt. Die moderne Histologie und Molekularbiologie sind heute in der Lage, benigne Verlaufsformen von solchen mit malignem Potential zu differenzieren.
Summary
Since the introduction of abdominal ultrasound liver lesions have been increasingly detected. Being usually diagnosed by chance these lesions create psychological stress among patients because a potential malignant disease has to be taken into consideration. The increasing use of oral contraceptives with high estrogen doses starting in the 1980s led to a rising incidence of adenomas, whose natural history differed from those described in surgical and autoptic studies. This fact brought about a change towards a modern pathophysiologic and prognostic differentiation. Current histologic and molecular biological techniques are able to distinguish benign adenomas from those with malignant potential.
Literatur
Bae KT, Tao C, Zhu F, Bost JE, et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol. 2009;4:719–25.
Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol. 1994 Nov;18(11):1078–91.
Buell JF, Tranchart H, Cannon R, et al. Management of benign hepatic tumors. Surg Clin North Am. 2010 Aug;90(4):719–35.
Gandolfi L, Leo P, Solmi L, et al. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut. 1991 Jun;32(6):677–80.
Elsayes KM, Narra VR, Yin Y, et al. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics. 2005 Sep;25(5):1299–320.
Di Stasi M, Caturelli E, De Sio I, et al. Natural history of focal nodular hyperplasia of the liver: an ultrasound study. J Clin Ultrasound. 1996 Sep;24(7):345–50.
Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg. 2010;27(1):39–45.
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006 Mar;43(3):515–24.
Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009 Aug;50(2):481–9.
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011 Sep 22;365(12):1118–27.
Ribes J, Cleries R, Esteban L, et al. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol. 2008 Aug;49(2):233–42.
Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35–50.
Sherman M, Bruix J, Porayko M, et al. Screening for hepatocellular carcinoma: the rationale for the American association for the study of liver diseases recommendations. Hepatology. 2012 Sep;56(3):793–6.
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012 Apr;56(4):908–43.
Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.
Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010 Aug;52(2):762–73.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012 Mar 31;379(9822):1245–55.
Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011 Jul;54(1):173–84.
Harewood GC, Baron TH, Stadheim LM, et al. Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol. 2004 Aug;99(8):1464–9.
Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008 Jul;48(1):308–21.
Liu S, Chan KW, Wang B, et al. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009 Oct;104(10):2617–24.
Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010 May 20;28(15):2584–90.
O’Grady JG. Treatment options for other hepatic malignancies. Liver Transpl. 2000 Nov;6(6 Suppl 2):S23–9.
Interessenkonflikt
Es besteht kein Interessenkonflikt.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Graziadei, I. Übersicht: Lebertumore. Wien Med Wochenschr 163, 109–112 (2013). https://doi.org/10.1007/s10354-013-0177-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-013-0177-5